HRT

 

 

 

 The North American Menopause Society (NAMS) has updated their position statement on menopausal hormone therapy (HT) for postmenopausal women. They considered the therapeutic benefit-risk ratio of HT at various times through menopause and beyond. Their view is that current evidence supports a consensus regarding the role of HT in postmenopausal women, when potential benefits and risks around the time of menopause are considered. The position statement lists all these areas along with explanatory comments. Areas that vary from a previous 2008 position statement are noted. A suggested reading list of key references published since the last statement is also provided. They conclude that recent data support the initiation of HT around the time of menopause to treat menopause-related symptoms; to treat or reduce the risk of certain disorders, such as osteoporosis or fractures in select postmenopausal women; or both. The benefit-risk ratio for menopausal HT is favorable for women who initiate HT close to menopause but decreases in older women and with time since menopause in previously untreated women.

Access this Position Statement and others from the Menopause Society here.